ANAPTYSBIO INC. - COMMON STOCK

AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis

02 10 2021 12:00:00 提供 Nasdaq GlobeNewswire

AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

09 9 2021 16:05:00 提供 Nasdaq GlobeNewswire

FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors

17 8 2021 16:32:07 提供 Nasdaq GlobeNewswire

AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference

27 5 2021 16:15:00 提供 Nasdaq GlobeNewswire

AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates

04 5 2021 16:05:01 提供 Nasdaq GlobeNewswire

European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe

23 4 2021 10:31:07 提供 Nasdaq GlobeNewswire

FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer

22 4 2021 16:12:22 提供 Nasdaq GlobeNewswire

AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors

12 4 2021 16:00:00 提供 Nasdaq GlobeNewswire

AnaptysBio Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Pipeline Updates

25 2 2021 16:05:01 提供 Nasdaq GlobeNewswire

AnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare Conference

07 1 2021 16:15:00 提供 Nasdaq GlobeNewswire